Lethal­ly se­vere neu­ro­tox­i­c­i­ty con­tin­ues to haunt Juno’s CAR-T pipeline

With the on­col­o­gy world look­ing for an up­date on the lead­ing CAR-T play­ers at ASH af­ter Juno Ther­a­peu­tics $JUNO put its lead pro­gram for JCAR015 back on clin­i­cal hold fol­low­ing 2 new deaths from cere­bral ede­ma, the biotech was forced to con­cede Sat­ur­day that in­ves­ti­ga­tors had tracked 6 cas­es of se­vere, grade 3-5 neu­ro­tox­i­c­i­ty out of 24 pa­tients in a sep­a­rate JCAR014 tri­al for chron­ic lym­pho­cyt­ic leukemia. And one of the pa­tients died af­ter de­vel­op­ing grade 5 cy­tokine re­lease syn­drome and cere­bral ede­ma (brain swelling).

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN